Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
Frontiers in Immunology|July 26, 2021
Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic LeukemiaAnnika Nelde, Yacine Maringer, Tatjana Bilich, et al.
Science Translational Medicine|March 16, 2021
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individualsTatjana Bilich, Annika Nelde, Jonas S Heitmann, et al.
Frontiers in Oncology|April 12, 2024
FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusionChristopher Hackenbruch, Jens Bauer, Jonas S Heitmann, et al.
Oncogene|October 18, 2016
OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumorsL A Jung, A Gebhardt, W Koelmel, et al.
Frontiers in Immunology|May 1, 2026
Mouse TAPBPR shows functional similarity to human TAPBPR in shaping the MHC-I immunopeptidomeJuliana Bernardi Aggio, Marcel Wacker, William Guo, et al.
Clinical & Translational Immunology|September 6, 2021
Landscape of T-cell repertoires with public COVID-19-associated T-cell receptors in pre-pandemic risk cohortsDonjete Simnica, Christoph Schultheiß, Malte Mohme, et al.
The Journal of Experimental Medicine|December 24, 2019
Identification of HCMV-derived T cell epitopes in seropositive individuals through viral deletion modelsMaren Lübke, Stefanie Spalt, Daniel J Kowalewski, et al.
Gastroenterology|October 3, 2020
Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in MiceBernd Heinrich, Zachary J Brown, Laurence P Diggs, et al.
Journal for Immunotherapy of Cancer|April 15, 2025
PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy developmentSteffen Lemke, Marissa L Dubbelaar, Patrick Zimmermann, et al.
Journal of Hematology & Oncology|August 16, 2023
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual diseaseJonas S Heitmann, Richard F Schlenk, Daniela Dörfel, et al.
Pageof 10